SAN DIEGO, Jan. 10, 2019 /PRNewswire/ -- BioFluidica, a privately held cancer diagnostics company, has been awarded an SBIR Phase II National Institutes of Health grant of $1.7 million for a clinical trial in support of "Increased sensitivity of minimal residual disease monitoring using peripheral blood in pediatric patients with acute lymphoblastic leukemia."
Acute lymphoblastic leukemia (ALL) is the most common malignant disease in childhood and accounts for approximately 30% of all cancers diagnosed before the age of 18 years. The primary cause of death for ALL patients is disease relapse. Therefore, monitoring for minimal residual disease (MRD) is considered the most powerful predictor of outcome in acute leukemias.
Rolf Muller, CEO of BioFluidica, states that with BioFluidica's technology, "We are able to program microfluidic chips to isolate any kind of diagnostically relevant cell from blood samples, whether from solid tumors or blood cancer. In the case of ALL we are detecting complex panels of Circulating Leukemic Cells (CLCs) to monitor cancer recurrence. The expansion of BioFluidica's technology into the blood-born cancers is added to the clinical validation we have already achieved from 9 other cancers including lung, breast, pancreatic, prostate, and colorectal cancer. The high through-put instrumentation for cell isolation will now be used in clinical trials."
CONTACT US: [email protected]
Core Screening Facility #1
10835 Road to the Cure
San Diego, Ca. 92121
"The Liquid Scan ®, hope for millions."